CG Oncology (CGON) Treasury Shares (2023)
CG Oncology's (CGON) quarterly Treasury Shares came in at $165373.0 in Q1 2026, down 0.58% on a QoQ basis from $166342.0 in Q4 2025.
Analysis
CG Oncology (CGON) Treasury Shares (2023) Analysis & Trends
CG Oncology (CGON) has 3 years of Treasury Shares data on file, last reported at $165373.0 in Q1 2026.
- Quarterly Treasury Shares changed N/A year-over-year to $165373.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165373.0 (changed N/A YoY) and the FY2025 annual result came in at $166342.0, changed N/A from the prior year.
- Treasury Shares slipped to $165373.0 in Q1 2026, from $166342.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $81.6 million in Q4 2023 to a low of $94624.0 in Q3 2025.
- A 3-year average of $33.3 million and a median of $23.9 million in 2023 frame the typical range for Treasury Shares.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 2.72 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | CG Oncology | 6.56 Bn | 6.56 Bn | -2.77 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 112.42 Mn |
| Dec 31, 2023 | 112.42 Mn |
| Sep 30, 2023 | 112.42 Mn |
| Sep 30, 2023 | 112.42 Mn |
| Jun 30, 2023 | 112.42 Mn |
| Jun 30, 2023 | 112.42 Mn |
| Mar 31, 2023 | 112.42 Mn |
| Mar 31, 2023 | 112.42 Mn |